ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Total Equity
ScinoPharm Taiwan Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Total Equity
NT$10.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Total Equity
NT$7.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Total Equity
NT$7.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Total Equity
NT$5.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Total Equity
NT$21.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
22%
|
CAGR 10-Years
10%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Total Equity
NT$5.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Total Equity?
Total Equity
10.5B
TWD
Based on the financial report for Dec 31, 2024, ScinoPharm Taiwan Ltd's Total Equity amounts to 10.5B TWD.
What is ScinoPharm Taiwan Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
1%
Over the last year, the Total Equity growth was 2%.
You don't have any saved screeners yet